• Je něco špatně v tomto záznamu ?

The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database

A. Janikova, Z. Bortlicek, V. Campr, N. Kopalova, K. Benesova, M. Hamouzova, D. Belada, V. Prochazka, R. Pytlik, S. Vokurka, J. Pirnos, J. Duras, H. Mocikova, J. Mayer, M. Trneny,

. 2018 ; 97 (4) : 669-678. [pub] 20180109

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18010206

Grantová podpora
NV16-31092A MZ0 CEP - Centrální evidence projektů

The aim of this study is to assess the incidence, risk factors, and outcome of biopsy-proven transformation in follicular lymphoma (FL) patients in the rituximab era. Transformation was analyzed in 1233 patients with initially diagnosed FL grades 1-3A, identified between 2002 and 2012 in the prospectively maintained Czech Lymphoma Study Group database. Only patients with histologically proven transformation (HT) were included. HT occurred in 58 cases at a median of 3.0 years from the initial FL diagnosis; the HT rate was 4% at 5 years. Transformation occurred most frequently at the first relapse (84% patients). Median OS from the HT was 2.5 years (95% CI 0.4-4.6) and 6-year OS with HT was shorter compared to all FLs (60 vs. 83.9%; 95% CI). A bulky tumor (≥ 10 cm), increased lactate dehydrogenase, age ≥ 60 years, and International Prognostic Index (intermediate/high risk), but not Follicular Lymphoma International Prognostic Index, were associated with transformation (p < 0.05). In the first line, 70% of patients received rituximab (including 36% rituximab maintenance), 57% CHOP-like regimens, and 2.6% of patients were treated with fludarabine-based therapy, whereas 11% of patients were watched only. The patients treated with R-CHOP in the first line (n = 591) showed the transformation rate at 5 years of 4.23% (95% CI 2.52-5.93); subsequent rituximab maintenance (n = 276) vs. observation (n = 153) was associated with a lower transformation rate (p.033; HR 3.29; CI 1.10-9.82). The transformation rate seems to be lower than in previous series, which may be influenced by broad use of rituximab, but prognosis of HT developed during therapy continues to be poor.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18010206
003      
CZ-PrNML
005      
20250424111550.0
007      
ta
008      
180404s2018 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00277-017-3218-0 $2 doi
035    __
$a (PubMed)29318369
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Janikova, Andrea $u Department of Internal Medicine-Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic. janikova.andrea@fnbrno.cz. Department of Hematology and Oncology, University Hospital Brno and Masaryk University Brno, Jihlavska 20, 625 00, Brno, Czech Republic. janikova.andrea@fnbrno.cz.
245    14
$a The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database / $c A. Janikova, Z. Bortlicek, V. Campr, N. Kopalova, K. Benesova, M. Hamouzova, D. Belada, V. Prochazka, R. Pytlik, S. Vokurka, J. Pirnos, J. Duras, H. Mocikova, J. Mayer, M. Trneny,
520    9_
$a The aim of this study is to assess the incidence, risk factors, and outcome of biopsy-proven transformation in follicular lymphoma (FL) patients in the rituximab era. Transformation was analyzed in 1233 patients with initially diagnosed FL grades 1-3A, identified between 2002 and 2012 in the prospectively maintained Czech Lymphoma Study Group database. Only patients with histologically proven transformation (HT) were included. HT occurred in 58 cases at a median of 3.0 years from the initial FL diagnosis; the HT rate was 4% at 5 years. Transformation occurred most frequently at the first relapse (84% patients). Median OS from the HT was 2.5 years (95% CI 0.4-4.6) and 6-year OS with HT was shorter compared to all FLs (60 vs. 83.9%; 95% CI). A bulky tumor (≥ 10 cm), increased lactate dehydrogenase, age ≥ 60 years, and International Prognostic Index (intermediate/high risk), but not Follicular Lymphoma International Prognostic Index, were associated with transformation (p < 0.05). In the first line, 70% of patients received rituximab (including 36% rituximab maintenance), 57% CHOP-like regimens, and 2.6% of patients were treated with fludarabine-based therapy, whereas 11% of patients were watched only. The patients treated with R-CHOP in the first line (n = 591) showed the transformation rate at 5 years of 4.23% (95% CI 2.52-5.93); subsequent rituximab maintenance (n = 276) vs. observation (n = 153) was associated with a lower transformation rate (p.033; HR 3.29; CI 1.10-9.82). The transformation rate seems to be lower than in previous series, which may be influenced by broad use of rituximab, but prognosis of HT developed during therapy continues to be poor.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a antracykliny $x škodlivé účinky $x terapeutické užití $7 D018943
650    _2
$a protinádorové látky imunologicky aktivní $x škodlivé účinky $x terapeutické užití $7 D000074322
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
650    _2
$a biopsie $7 D001706
650    _2
$a nádorová transformace buněk $x účinky léků $x patologie $7 D002471
650    _2
$a kohortové studie $7 D015331
650    _2
$a Česká republika $x epidemiologie $7 D018153
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a incidence $7 D015994
650    _2
$a folikulární lymfom $x farmakoterapie $x epidemiologie $x patologie $x prevence a kontrola $7 D008224
650    _2
$a udržovací chemoterapie $x škodlivé účinky $7 D060046
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a registrace $7 D012042
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a rituximab $x škodlivé účinky $x terapeutické užití $7 D000069283
650    _2
$a sekundární prevence $7 D055502
650    _2
$a analýza přežití $7 D016019
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bortlicek, Zbynek $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Campr, Vit $u Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University and Faculty Hospital in Motol, Prague, Czech Republic.
700    1_
$a Kopálová, Nataša $u Department of Internal Medicine-Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic. $7 xx0331481
700    1_
$a Benesova, Katerina $u 1st Department of Medicine, First Medical Faculty, Charles University and General University Hospital, Prague, Czech Republic.
700    1_
$a Hamouzova, Michaela $u 1st Department of Medicine, First Medical Faculty, Charles University and General University Hospital, Prague, Czech Republic.
700    1_
$a Belada, David $u 4th Department of Internal Medicine-Hematology, Faculty of Medicine, Charles University Hospital, Hradec Králové, Czech Republic.
700    1_
$a Prochazka, Vit $u Department of Hemato-oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic.
700    1_
$a Pytlik, Robert $u 1st Department of Medicine, First Medical Faculty, Charles University and General University Hospital, Prague, Czech Republic.
700    1_
$a Vokurka, Samuel $u Department of Hemato-oncology, Charles University and University Hospital Pilsen, Pilsen, Czech Republic.
700    1_
$a Pirnos, Jan $u Department of Oncology, Hospital Ceske Budejovice, Ceske Budejovice, Czech Republic.
700    1_
$a Duras, Juraj $u Department of Clinical Hematology, Teaching Hospital Ostrava, Ostrava, Czech Republic.
700    1_
$a Mocikova, Heidi $u Internal Clinic of Haematology, 3rd Faculty of Medicine, University Hospital Kralovske Vinohrady, Prague, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Mayer, Jiri $u Department of Internal Medicine-Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic.
700    1_
$a Trneny, Marek $u 1st Department of Medicine, First Medical Faculty, Charles University and General University Hospital, Prague, Czech Republic.
773    0_
$w MED00000424 $t Annals of hematology $x 1432-0584 $g Roč. 97, č. 4 (2018), s. 669-678
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29318369 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20250424111549 $b ABA008
999    __
$a ok $b bmc $g 1287691 $s 1007018
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 97 $c 4 $d 669-678 $e 20180109 $i 1432-0584 $m Annals of hematology $n Ann Hematol $x MED00000424
GRA    __
$a NV16-31092A $p MZ0
LZP    __
$a Pubmed-20180404

Najít záznam

Citační ukazatele

Možnosti archivace